Nasacort AQ Switch Gets NDAC Nod Despite Pediatric Use Concerns
This article was originally published in The Tan Sheet
Executive Summary
FDA’s Nonprescription Drugs Advisory Committee voted 10 to 6, with two abstentions, in favor of Sanofi’s application to switch the intranasal corticosteroid Nasacort AQ. Chief among the panel’s concerns is the risk of growth suppression in young children who could use the OTC drug without physician monitoring.
You may also be interested in...
OTC Allergy Drug Use Increases: A Symptom With Multiple Causes
CHPA says growing use of allergy OTCs from 2009 through 2015 in the US is a sign of more consumers prioritizing self-care over using health care services, but allergy specialists say their patients often have to start with an OTC even when they have a prescription.
OTC Allergy Drug Use Increases: A Symptom With Multiple Causes
CHPA says growing use of allergy OTCs from 2009 through 2015 in the US is a sign of more consumers prioritizing self-care over using health care services, but allergy specialists say their patients often have to start with an OTC even when they have a prescription.
Nonprescription Nasonex Gains UK Regulator’s Support
The UK MHRA is accepting comments on its recommendation to allow pharmacy sales of nonprescription Nasonex Allergy Control (mometasone furoate/100 mcg).